Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health (JAGX) announced that Napo Pharmaceuticals is sponsoring an intestinal failure panel in Abu Dhabi on October 30, 2026. The panel, titled Intestinal Barrier Beyond Total Parenteral Nutrition, is part of the 2nd Best of Elite Ped-GI meeting. Participants include Dr. Mohamad Miqdady, Dr. Christos Tzivinikos and Jaguar's chief scientific officer, Pravin Chaturvedi.
Ongoing studies of oral liquid crofelemer in children with intestinal failure showed reductions in weekly parenteral support needs and support normalized to body weight after more than one year of oral dosing. Parenteral support supplies nutrition or fluids intravenously. Jaguar plans a mid-2027 New Drug Application filing for microvillus inclusion disease.
Jaguar Health (NASDAQ: JAGX) declared a special stock dividend payable October 15, 2026, in the form of Series R Convertible Preferred Stock. Eligibility is limited to holders of voting common stock and certain warrants with dividend rights at the close of business on October 13, 2026. Each preferred share will convert into five common shares on November 2, 2026.
Jaguar continues evaluating strategic alternatives and developing oral crofelemer for rare intestinal failure diseases. The company plans a mid-2027 New Drug Application filing, seeking approval for crofelemer to treat microvillus inclusion disease.
Jaguar Health (JAGX) announced that an abstract on preliminary adult short bowel syndrome study results was accepted for presentation at ACG 2026. The abstract covers an ongoing open-label study of crofelemer in adults with short bowel syndrome and intestinal failure (SBS-IF). The meeting runs October 9–14, 2026.
Napo Pharmaceuticals is also conducting a controlled Phase 2 trial in adults with Type 1 short bowel syndrome, with results expected early in the second half of 2027. Previously presented pediatric investigations reported reduced weekly parenteral support needs after more than one year of oral liquid crofelemer, with no significant clinical or laboratory abnormalities. Jaguar plans a drug application for microvillus inclusion disease in mid-2027.
Jaguar Health (JAGX) and family company Napo Pharmaceuticals received U.S. Food and Drug Administration waivers of 2027 fiscal year fees for two crofelemer-based products. Napo obtained a waiver of the Prescription Drug User Fee Act (PDUFA) fee for Mytesi (crofelemer delayed-release tablets), an FDA-approved prescription drug for symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, which is commercialized in the U.S. by Future Pak.
Jaguar separately received a 2027 fiscal year fee waiver from the FDA’s Center for Veterinary Medicine for Canalevia-CA1, its conditionally approved prescription drug for treatment of chemotherapy-induced diarrhea in dogs, also commercialized in the U.S. by Future Pak. The announcement also reiterates the Jaguar group’s broader focus on plant-derived prescription drugs for gastrointestinal and mental health indications.
Jaguar Health (JAGX) will implement a 1-for-15 reverse stock split of its issued and outstanding common stock on September 17, 2026 to support compliance with Nasdaq listing standards.
On the effective date, every fifteen shares of common stock outstanding immediately prior will automatically be reclassified into one share, with no change to par value, and the stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market under the symbol JAGX. The new CUSIP for the post-split common stock is 47010C854. No fractional shares will be issued; stockholders otherwise entitled to a fraction will receive a cash payment in lieu of fractional shares. The reverse split was approved at the April 2026 Special Meeting of Stockholders, as described in a definitive proxy statement filed March 24, 2026. Equiniti Trust Company will act as exchange agent, and holders in street name are not required to take action.
Jaguar Health (JAGX) reported that all randomized pediatric patients with microvillus inclusion disease (MVID) in Napo Pharmaceuticals' pivotal crossover trial have entered the single-blind extension phase to receive blinded doses of crofelemer as adjunctive therapy to parenteral support (PS).
The ongoing trial is being conducted at multiple centers in the United States, European Union, and United Arab Emirates and is expected to support a New Drug Application (NDA) filing for the MVID indication in mid-2027. An independent Data Monitoring Committee evaluated safety and tolerability during the randomized double-blind crossover period and authorized continuation of active crofelemer treatment in the extension phase. Previous investigational data in pediatric intestinal failure (IF) due to MVID and short bowel syndrome with IF (SBS-IF) showed substantial reductions in weekly PS needs, including up to a 48% reduction in PS normalized to body weight in one MVID patient and up to 40% in two SBS-IF patients after more than 12 months of high-dose oral crofelemer.
Jaguar Health (JAGX) launched Neonorm Dog, a plant-based, non-prescription product now available on Amazon to support normal stool consistency and gastrointestinal (GI) fluid balance in dogs.
The product extends Jaguar’s existing Neonorm franchise beyond foals and calves, using a standardized botanical extract from the sustainably harvested Croton lechleri tree that acts locally in the gut. Jaguar describes Amazon availability as a key element of Neonorm Dog’s commercial launch and expects the product to be offered soon through additional online and animal health retail channels, including Chewy. Neonorm Dog is positioned as a non-antibiotic option for pet owners managing common episodes of loose stools.
Jaguar Health (JAGX) announced that affiliate Napo Pharmaceuticals is providing its novel liquid oral crofelemer formulation for compassionate use to an infant with intestinal failure (IF) due to congenital sodium diarrhea caused by a GUCY2C mutation.
The company remains focused on developing crofelemer as adjunctive therapy to parenteral support (PS) for pediatric IF diseases, including microvillus inclusion disease (MVID) and short bowel syndrome with IF (SBS-IF). Ongoing pediatric studies of liquid oral crofelemer have shown reductions of up to 48% and 40% in weekly PS requirements normalized to body weight in MVID and SBS-IF patients, respectively, after more than 12 months of high-dose therapy, with no significant clinical or laboratory abnormalities reported.
Jaguar has completed the randomized double-blind treatment phase of its pivotal trial in pediatric MVID and plans to file an NDA for crofelemer for MVID in mid-2027, and may seek Breakthrough Therapy Designation based on the trial data.
Jaguar Health (NASDAQ:JAGX) announced the initiation of the commercial launch of Neonorm Dog, a non-prescription, plant-based product designed to support normal stool consistency and gastrointestinal (GI) fluid balance in dogs. The product extends Jaguar's existing Neonorm franchise, which currently includes Neonorm Foal and Neonorm Calf.
Neonorm Dog uses a standardized botanical extract from the sustainably harvested Croton lechleri tree, acting locally in the gut, and is positioned as a science-based option for managing episodes of loose stools in dogs. Jaguar expects Neonorm Dog to be available shortly through select online and animal health retail channels, including Amazon and Chewy, aiming to broaden the company’s commercial footprint in the companion animal market and increase awareness of the Neonorm brand among pet owners, veterinarians, and animal health retailers.
Jaguar Health (NASDAQ:JAGX) reported second-quarter 2026 net revenue of $1.2 million, down 59% year over year, as product revenue fell 60% to $1.18 million following the U.S. commercialization transfer of Mytesi and Canalevia-CA1 to Future Pak affiliate Woodward Specialty.
License and grant revenue were $43,000. Loss from operations narrowed to $7.6 million from $8.0 million, helped by operating expense reductions, including a drop in sales and marketing expense from about $2.5 million to roughly $5,000. Net loss attributable to common stockholders increased to $12.7 million. Non-GAAP recurring EBITDA was a loss of $8.4 million, versus a $7.9 million loss a year earlier.
According to Jaguar Health, it satisfied closing conditions to receive a non-dilutive $2 million holdback from Future Pak and continues advancing crofelemer for rare intestinal failure diseases, targeting completion of the NDA clinical package for microvillus inclusion disease by end of 2026 and an NDA filing in Q2 2027.